Literature DB >> 12642786

Cholesteryl ester transfer protein: gathering momentum as a genetic marker and as drug target.

Andreas Ritsch1, Josef R Patsch.   

Abstract

PURPOSE OF REVIEW: Cholesteryl ester transfer protein facilitates the exchange of neutral lipids between HDL and apolipoprotein B containing lipoproteins, which hold powerful opposing roles as risk factors for coronary artery disease. The question as to whether cholesteryl ester transfer protein promotes or protects from atherosclerosis, however, has not been answered. RECENT
FINDINGS: This review considers studies dealing with cholesteryl ester transfer protein variants and their effect on blood lipids in various metabolic and clinical settings. Other studies discussed deal with the association between the transfer protein and cardiovascular disease. Research on the biological activity of the cholesteryl ester transfer protein molecule is described including a first clinical study where pharmacological inhibition of the protein proved to be effective in raising HDL cholesterol.
SUMMARY: Data concerning the potential marker role of cholesteryl ester transfer protein, although accumulating, are still inconclusive and, at present, not useful for clinical decision making. Inhibition of the protein was demonstrated to be feasible and appears to be promising.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12642786     DOI: 10.1097/00041433-200304000-00009

Source DB:  PubMed          Journal:  Curr Opin Lipidol        ISSN: 0957-9672            Impact factor:   4.776


  5 in total

1.  The thyromimetic T-0681 protects from atherosclerosis.

Authors:  Ivan Tancevski; Andreas Wehinger; Egon Demetz; Julia Hoefer; Philipp Eller; Eva Huber; Ursula Stanzl; Kristina Duwensee; Kristina Auer; Wilfried Schgoer; Volker Kuhn; Catherine Fievet; Frans Stellaard; Mats Rudling; Bernhard Foeger; Josef R Patsch; Andreas Ritsch
Journal:  J Lipid Res       Date:  2008-12-22       Impact factor: 5.922

2.  Effects of weight loss on lipid transfer proteins in morbidly obese women.

Authors:  Markus W Laimer; Julia Engl; Alexander Tschoner; Susanne Kaser; Andreas Ritsch; Tobias Tatarczyk; Markus Rauchenzauner; Helmut Weiss; Franz Aigner; Josef R Patsch; Christoph F Ebenbichler
Journal:  Lipids       Date:  2009-09-30       Impact factor: 1.880

Review 3.  The resurgence of thyromimetics as lipid-modifying agents.

Authors:  Ivan Tancevski; Philipp Eller; Josef R Patsch; Andreas Ritsch
Journal:  Curr Opin Investig Drugs       Date:  2009-09

4.  Cholesteryl ester transfer protein and mortality in patients undergoing coronary angiography: the Ludwigshafen Risk and Cardiovascular Health study.

Authors:  Andreas Ritsch; Hubert Scharnagl; Philipp Eller; Ivan Tancevski; Kristina Duwensee; Egon Demetz; Anton Sandhofer; Bernhard O Boehm; Bernhard R Winkelmann; Josef R Patsch; Winfried März
Journal:  Circulation       Date:  2010-01-11       Impact factor: 29.690

5.  The liver-selective thyromimetic T-0681 influences reverse cholesterol transport and atherosclerosis development in mice.

Authors:  Ivan Tancevski; Egon Demetz; Philipp Eller; Kristina Duwensee; Julia Hoefer; Christiane Heim; Ursula Stanzl; Andreas Wehinger; Kristina Auer; Regina Karer; Julia Huber; Wilfried Schgoer; Miranda Van Eck; Jonathan Vanhoutte; Catherine Fievet; Frans Stellaard; Mats Rudling; Josef R Patsch; Andreas Ritsch
Journal:  PLoS One       Date:  2010-01-15       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.